Willingness to use tamoxifen to prevent breast cancer among diverse women
- PMID: 22315131
- PMCID: PMC4039196
- DOI: 10.1007/s10549-012-1960-5
Willingness to use tamoxifen to prevent breast cancer among diverse women
Abstract
Use of chemoprevention to prevent development of breast cancer among high-risk women has been limited despite clinical evidence of its benefit. Our goals were to determine whether knowledge of the benefits and risks of tamoxifen affects a woman's willingness to take it to prevent breast cancer, to define factors associated with willingness to take tamoxifen, and to evaluate race/ethnic differences. Women, ages 50-80, who identified as African American, Asian, Latina, or White, and who had at least one visit to a primary care physician in the previous 2 years, were recruited from ambulatory practices. After a screening telephone survey, women completed an in-person interview in their preferred language. Multivariate regression models were constructed to examine the associations of demographic characteristics, numeracy, breast cancer history, and health knowledge with willingness to take tamoxifen. Over 40% of the women reported they would likely take tamoxifen if determined to be at high risk, and 31% would be somewhat likely to do so. Asian women, those with no insurance, and those with less than high school education were significantly more likely to be willing to take tamoxifen. Higher scores on numeracy and on breast cancer knowledge were also associated with willingness to take tamoxifen. A higher tamoxifen knowledge score was inversely related to willingness to take the drug. Factors affecting women's willingness to take breast cancer chemoprevention drugs vary and are not determined solely by knowledge of risk/benefit or risk perception.
Conflict of interest statement
Figures
Similar articles
-
Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.J Natl Cancer Inst. 2003 Apr 2;95(7):526-32. doi: 10.1093/jnci/95.7.526. J Natl Cancer Inst. 2003. PMID: 12671020
-
"I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction.Ethn Dis. 2005 Summer;15(3):365-72. Ethn Dis. 2005. PMID: 16108294 Clinical Trial.
-
Colorectal cancer screening: what do women from diverse ethnic groups want?J Gen Intern Med. 2013 Feb;28(2):239-46. doi: 10.1007/s11606-012-2210-6. Epub 2012 Sep 12. J Gen Intern Med. 2013. PMID: 22968796 Free PMC article.
-
Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.J Natl Cancer Inst. 1999 Nov 3;91(21):1829-46. doi: 10.1093/jnci/91.21.1829. J Natl Cancer Inst. 1999. PMID: 10547390 Review.
-
American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.J Clin Oncol. 1999 Jun;17(6):1939-55. doi: 10.1200/JCO.1999.17.6.1939. J Clin Oncol. 1999. PMID: 10561236 Review.
Cited by
-
Comparing Breast Cancer and Cardiovascular Disease Risk and Use of Chemoprevention and Statins among Women with High-risk Breast Lesions.Cancer Prev Res (Phila). 2023 Dec 1;16(12):661-667. doi: 10.1158/1940-6207.CAPR-23-0181. Cancer Prev Res (Phila). 2023. PMID: 37976537 Free PMC article.
-
Breast Nurse Intervention to Improve Adherence to Endocrine Therapy Among Breast Cancer Patients in South Ethiopia.Oncologist. 2022 Aug 5;27(8):e650-e660. doi: 10.1093/oncolo/oyac081. Oncologist. 2022. PMID: 35524760 Free PMC article. Clinical Trial.
-
Factors Associated with Women's Unwillingness to Decrease Alcohol Intake to Decrease Breast Cancer Risk.J Prim Care Community Health. 2021 Jan-Dec;12:21501327211000211. doi: 10.1177/21501327211000211. J Prim Care Community Health. 2021. PMID: 33749348 Free PMC article.
-
Socio-culturally mediated factors and lower level of education are the main influencers of functional cervical cancer literacy among women in Mayuge, Eastern Uganda.Ecancermedicalscience. 2020 Jan 21;14:1004. doi: 10.3332/ecancer.2020.1004. eCollection 2020. Ecancermedicalscience. 2020. PMID: 32104206 Free PMC article.
-
Understanding Decision Making about Breast Cancer Prevention in Action: The Intersection of Perceived Risk, Perceived Control, and Social Context: NRG Oncology/NSABP DMP-1.Med Decis Making. 2019 Apr;39(3):217-227. doi: 10.1177/0272989X19827258. Epub 2019 Feb 25. Med Decis Making. 2019. PMID: 30803311 Free PMC article.
References
-
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66. - PubMed
-
- Chlebowski RT. Breast cancer risk reduction: strategies for women at increased risk. Annu Rev Med. 2002;53:519–540. - PubMed
-
- AHRQ. The guide to clinical preventive services. Recommendations of the US preventive services task force. The Agency for Healthcare Research and Quality; 2007.
-
- Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–1388. - PubMed
-
- Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Jr, Wade JL, 3rd, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727–2741. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
